Compare · IRMD vs RMD
IRMD vs RMD
Side-by-side comparison of iRadimed Corporation (IRMD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRMD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 23.9x IRMD ($1.19B).
- Over the past year, IRMD is up 55.6% and RMD is down 22.6% - IRMD leads by 78.2 points.
- RMD has been more active in the news (6 items in the past 4 weeks vs 5 for IRMD).
- RMD has more recent analyst coverage (25 ratings vs 1 for IRMD).
- Company
- iRadimed Corporation
- ResMed Inc.
- Price
- $94.38+0.33%
- $194.31-0.87%
- Market cap
- $1.19B
- $28.44B
- 1M return
- +8.63%
- -6.03%
- 1Y return
- +55.62%
- -22.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 5
- 6
- Recent ratings
- 1
- 25
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IRMD
- Director Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $657,265 worth of shares (7,500 units at $87.64) as part of a pre-agreed trading plan (SEC Form 4)
- IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation
- CEO, President, Chairman Susi Roger E. sold $631,341 worth of shares (7,500 units at $84.18) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $642,862 worth of shares (7,500 units at $85.71) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.